Clinical trial NCT06038396: A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Official title: A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumor
Lead sponsor: RemeGen Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-09-14
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.


Eligibility criteria: Inclusion Criteria:

1. Be able to participate in the study voluntarily and willing to provide written informed consent.
2. male or female 18 ≤ age ≤ 75 years old.
3. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
4. The expected survival ≥12 weeks.
5. Enrollment of subjects with locally advanced or metastatic gastric adenocarcinoma/adenocarcinoma of the gastroesophageal junction who have a histologically confirmed diagnosis and have failed standard therapy.
6. Subjects who received ≤2 prior systemic therapies.
7. Subjects agree to provide tumor tissue specimens for Claudin 18.2 and PD-L1 expression levels during the screening period. Samples should have moderate to high expression of Claudin 18.2 by membrane staining.
8. According to the RECIST v1.1, there is at least one measurable target lesion.
9. Sufficient heart, bone marrow, liver and kidney functions.
10. Fertile male or female subjects must agree to take effective contraceptive measures during the study period and for 6 months after the end of the last dose, such as double-barrier contraceptive methods(eg. condoms), oral or injectable contraceptives, intrauterine.

Exclusion Criteria:

1. Pregnant women, breastfeeding women or women with a positive blood pregnancy test result during the screening period (non-fertile women do not need to undergo a pregnancy test, such as women with a previous hysterectomy and/or bilateral oophorectomy or amenorrhea ≥12 months).
2. Subjects with active hepatitis B (HBsAg positivity and HBV DNA titre higher than the normal upper limit), active hepatitis C (HCVAb positivity and HCV RNA titre higher than the normal upper limit), and positive human immunodeficiency virus antibody (HIV-Ab) results during the screening period.
3. Subjects with a history of other acquired or congenital immunodeficiency diseases, or who have undergone organ or bone marrow transplantation.
4. Subjects who have previously received monoclonal antibody, double antibody targeting drugs, ADC, CAR-T and other therapeutic drugs targeting Claudin 18.2 or other ADCs with MMAE payload; or have participated in clinical trials and received investigational drugs within 4 weeks before the first dose.
5. Have vaccinated within 4 weeks prior to the first dose or plan to receive any live vaccine during the study.
6. Subjects are atallergic to the ingredients or excipients of the experimental drug.
7. Subjects who have received anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy, or targeted therapy) within 4 weeks or less than 5 half-lives of the experimental drug prior to the start of the first dose; or who have received anti-tumor therapy with traditional Chinese medicine or immunomodulators within 2 weeks prior to the start of the first dose.
8. The toxicity of previous anti-tumor therapy has not returned to the level 0 or 1 as defined by NCI-CTCAE v5.0 (except for alopecia, pigmentation and other long-term toxicity ≤2 that cannot be recovered which was defined by investigators).
9. The clinical symptoms of pleural effusion, abdominal effusion, or pericardial effusion that requires drainage.
10. Active infection within 2 weeks prior to the first dose that requires systemic anti-inflammatory therapy.
11. Complicating other diseases that seriously endanger the safety of the subjects or affect the completion of the study, such as peptic ulcer, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, renal failure and uncontrolled diabetes (Fasting blood glucose \> 8.5 mmol/L, HbA1C ≥7.5%).
12. The tumor lesion has a bleeding tendency or has received blood transfusion treatment within 4 weeks prior to the first dose.
13. During the screening period, QTc interval \>450 ms(male), QTc interval \>470ms(female); previous family or personal history of long/short QT interval syndrome; A history of ventricular arrhythmia deemed clinically significant by the investigator, or currently receiving antiarrhythmic medication, or implantation of arrhythmia defibrillation device.
14. Previous myocardial infarction (within 6 months prior to the first dose), severe or unstable angina, coronary or peripheral artery bypass grafting, heart failure grade 3\~4 defined by New York Heart Association (NYHA) and uncontrolled hypertension.
15. Experienced an arterial/venous thromboembolic event within 6 months prior to the study.
16. Active autoimmune disease that requires systemic treatment within 2 years prior to the study. Patients with vitiligo, psoriasis, alopecia or Grave's disease that not requires systemic treatment, hypothyroidism that only requires thyroid hormone replacement therapy, and type 1 diabetes only requires insulin replacement therapy may be included in the study.
17. Subjects with brain metastases and/or carcinomatous meningitis who have previously received related treatment may be considered for inclusion if their disease has been stable for at least 3 months, no imaging evidence of disease progression has been observed within 4 weeks prior to the first dose, all neurological symptoms have returned to baseline, and radiation, surgery, or steroid therapy has been discontinued at least 28 days prior to the first dose; cancerous meningitis should be excluded regardless of whether it is clinically stable.
18. Other malignant tumor within 5 years prior to the signature of informed consent.
19. Major surgery or interventional therapy was performed within 4 weeks prior to the first dose and did not fully recovered (except tumor biopsy and puncture).
20. For Phase II subjects:

    * Received an immune checkpoint inhibitor (anti-PD-1/PD-L1/CTLA-4 antibody) or other immune checkpoint inhibitor therapy within 28 days prior to the first treatment with the test drug;
    * Prior concurrent receipt of antitumor agents targeting VEGF/VEGFR and PD-1/PD-L1;
    * Experienced permanent discontinuation of immunotherapy due to toxicity of immune checkpoint inhibitor therapy prior to receiving administration of study drug;
    * Currently receiving anticoagulant medications (except for subjects on prophylactic doses of heparin).
21. A history of uncontrollable mental illness or subjects currently experiencing such conditions.
22. Subjects with poor compliance who are expected to be unable to complete the study.

Primary outcomes:
measure: Phase1: Dose limiting toxicity (DLT)
timeFrame: The first 3 weeks (21 days) after the start of dosing at each dose level
measure: Phase1/2: Adverse events (AEs)
timeFrame: [Time Frame: 15 months]
measure: Phase1: Maximum tolerated dose(MTD)
timeFrame: up to 12 months
measure: Phase1: Recommended Phase 2 Dose (RP2D)
timeFrame: up to 12 months
measure: Phase 2: Objective response rate (ORR)
timeFrame: 15 months
Secondary outcomes:
measure: Disease Control Rate (DCR)
timeFrame: 15 months
measure: Progression-free survival (PFS)
timeFrame: 15 months
measure: Duration of Remission (DOR)
timeFrame: 15 months
measure: Overall survival (OS)
timeFrame: 15 months
measure: Phase 1: Objective response rate (ORR)
timeFrame: 15 months
measure: Peak and valley concentrations of RC118, total antibody, and free MMAE
timeFrame: 15 months
measure: RC118 immunogenicity: The incidence, time of onset, duration of patients with anti-drug-antibody (ADA)
timeFrame: 15 months
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
city: Xiamen
country: China
facility: The First Affiliated Hospital of Xiamen University
state: Fujian
city: Wuwei
country: China
facility: Gansu Wuwei Tumour Hospital
state: Gansu
city: Meizhou
country: China
facility: Meizhou People's Hospital
state: Guangdong
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
state: Heilongjiang
city: Nanyang
country: China
facility: Nanyang Central Hospital
state: Henan
city: Xinyang
country: China
facility: Xinyang Central Hospital
state: Henan
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
state: Henan
city: Xuzhou
country: China
facility: The Affiliated Hospital of Xuzhou Medical University
state: Jiangsu
city: Xuzhou
country: China
facility: Xuzhou Central Hospital
state: Jiangsu
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical University
state: Shandong
city: Jinan
country: China
facility: Cancer Hospital of Shandong First Medical University
state: Shandong
city: Changzhi
country: China
facility: Changzhi People's Hospital
state: Shanxi
city: Chengdu
country: China
facility: West China Hospital Sichuan University
state: Sichuan
city: Neijiang
country: China
facility: The Second People's Hospital of Neijiang
state: Sichuan
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan University
Study officials:
affiliation: Shanghai Zhongshan Hospital
name: Tianshu Liu, ph.D
role: PRINCIPAL_INVESTIGATOR
References: